Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Dec 20, 2022 10:52pm
195 Views
Post# 35183808

RE:RE:RE:RE:RE:RE:RE:RE:RE:i-Dialco

RE:RE:RE:RE:RE:RE:RE:RE:RE:i-Dialco

"So when you look at that track record I'd say .33 is probably fair. Our science is solid and should be worth many dollars- but the way Seto and Co. are running the show makes it high risk. As their loss of control of Dialco has just shown us" - Hmmmmm

Again I say... "buy design"?

How convenient for some that it IS  trading at .33. ;) 

phase 1 separation of assets ( uncertain value, shareholders verklempt ) 

phase 2 monetization according to the ultimate buyer's agenda (IMO) 

Re PMX 
IMO the Goal to maximize MB by interim, and allow other evidence to accumulate/ mature/ add value ( eg RWE, CV-19 studies, Eden for label expansion)  Also to pick the perfect candidates ( quality over speed)  in the " confirmatory trial " that is "exceeding expectations."
Looks to me like a tortoise strategy to me. "Mgt incompetence " is a handy interim store front ( won't bore everyone with that analogy again) 



Oh and the other thing that they dare not do is to toot their own horn along the journey. That just attracts pesky followers that ask too many pesky questions.... and unnecessarily raises the cost of options, and future raises along the way.  Common but not always standard practice.  All IMO. 

I could be totally wrong and Seto is, as you say, dropping the ball big time and that he sucks at managing expectations. Maybe he's a patsy ( like Oswald was in a much bigger game) The fact that the the BoD has NOT acted on what others see as obvious incompetence suggests to me at least, that another explanation fits better. Or in other words an alternate and creative and tricky end game is afoot to borrow a phrase from the wise, infamous and at time notorious STT who's spirit lives on in a rather large group of equally keen observers.  ( or perhaps just an excuse for me to supply a timely soccer reference) . 


MM
 

 

<< Previous
Bullboard Posts
Next >>